FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W159611377> ?p ?o ?g. }

• W159611377 endingPage "3881" @default.
• W159611377 startingPage "3881" @default.
• W159611377 abstract "Abstract Background: Labile plasma iron (LPI) is a toxic, directly chelatable form of non-transferrin- bound iron that is produced continually in conditions of iron overload and, due to rapid uptake into hepatocytes, myocardium and endocrine tissues, leads to secondary expansion of the cellular iron pool. The sustained presence of an iron chelator in the plasma may help avoid accumulation of LPI, thereby minimizing iron-related morbidity and mortality. This analysis evaluates the effect of deferasirox on LPI levels in patients (pts) with transfusion-dependent anemias enrolled in the large-scale, prospective, 1-yr multicenter EPIC trial. Methods: Enrolled pts were aged ≥2 yrs, had transfusion-dependent anemia and serum ferritin (SF) levels of ≥1000 ng/mL, or <1000 ng/mL with a history of multiple transfusions (>20 transfusion episodes or >100 mL/kg of RBCs) and an R2 MRI-confirmed LIC >2 mg Fe/g dry weight (dw). Deferasirox starting dose was determined based on blood transfusion frequency. Dose adjustments in steps of 5–10 mg/kg/day (in the range 0–40 mg/kg/day) were based on SF trends and safety markers. Blood samples to measure LPI and assess the deferasirox pharmacokinetic profile were taken pre-administration and 2 hrs post administration at baseline and wks 12, 28 and 52. Results: LPI data are available from 1602 pts (825 M, 777 F; mean 30.4±23.0 yrs). Underlying anemias were: β-thalassemia (n=1029), myelodysplastic syndromes (MDS; n=305), aplastic anemia (AA; n=104), sickle cell disease (SCD; n=79), rare anemias (mostly hemolytic in nature) (n=42), and other conditions associated with anemias requiring transfusion (n=43). Mean LPI, pre and post deferasirox administration, at baseline and wks 12, 28 and 52 are shown in Table 1. Table 1. Mean LPI, pre and post deferasirox administration, at baseline and after repeat doses Baseline Week 12 Week 28 Week 52 Pre Post Pre Post Pre Post Pre Post NOTE: Data are mean LPI±SD (μmol/L); normal levels are 0–0.40 μmol/L All pts 0.89 ±1.84 0.33 ±1.59 0.30 ±0.90 0.11 ±0.56 0.27 ±0.87 0.11 ±0.62 0.47 ±1.35 0.30 ±1.33 β-thalassemia 1.25 ±2.34 0.58 ±2.10 0.40 ±1.07 0.15 ±0.67 0.34 ±0.94 0.13 ±0.72 0.60 ±1.55 0.39 ±1.52 MDS 0.53 ±0.63 0.02 ±0.11 0.08 ±0.28 0.02 ±0.10 0.15 ±0.88 0.03 ±0.18 0.14 ±0.32 0.02 ±0.07 AA 0.23 ±0.34 0.01 ±0.02 0.08 ±0.20 0.01 ±0.04 0.06 ±0.20 0.01 ±0.03 0.04 ±0.10 0.03 ±0.10 SCD 0.11 ±0.54 0.04 ±0.29 0.09 ±0.42 0.06 ±0.31 0.11 ±0.28 0.14 ±0.46 0.10 ±0.21 0.07 ±0.19 Rare anemias 0.50 ±0.55 0.01 ±0.04 0.05 ±0.13 0.01 ±0.03 0.06 ±0.18 0.01 ±0.03 0.29 ±0.52 0.02 ±0.03 Overall mean deferasirox dose during the 1-yr treatment period was 22.4±6.0 mg/kg/day (β-thalassemia, MDS, AA, SCD and rare anemias: 24.3±5.5, 19.3±5.7, 17.8±4.7, 20.2±3.8 and 18.6±5.6 mg/kg/day, respectively). At each time point, peak LPI levels observed just before deferasirox dosing were decreased compared with baseline and were mostly within the normal range from week 12 onwards in each underlying anemia. A small rebound at 52 wks was seen in the thalassemia sub-group: this could be associated with decreased compliance or other reasons, to be investigated further. In all pts, mean steady-state plasma concentration (ie pre-administration value) of deferasirox at wks 12, 28 and 52 was 32.9, 35.9 and 39.4 μmol/L, respectively. At each time point this was approximately half of the concentration value observed at 2 hrs post administration (84.4, 89.3 and 97.0 μmol/L, respectively). Conclusions: The results from this 1-yr study confirm the ability of once-daily deferasirox to provide sustained reduction in toxic LPI levels across various transfusion-dependent anemias, supporting previous data in pts with β-thalassemia. This is likely due to trough levels of deferasirox being within the therapeutic range, thereby preventing LPI levels rebounding between doses. Deferasirox therapy may therefore reduce unregulated tissue iron loading and prevent further end-organ damage in these pts." @default.
• W159611377 created "2016-06-24" @default.
• W159611377 creator A5013521713 @default.
• W159611377 creator A5026498330 @default.
• W159611377 creator A5030898208 @default.
• W159611377 creator A5036354175 @default.
• W159611377 creator A5049244658 @default.
• W159611377 creator A5053053769 @default.
• W159611377 creator A5058078318 @default.
• W159611377 creator A5069567664 @default.
• W159611377 creator A5072237761 @default.
• W159611377 creator A5081326206 @default.
• W159611377 creator A5085429434 @default.
• W159611377 date "2008-11-16" @default.
• W159611377 modified "2023-09-27" @default.
• W159611377 title "Effect of Deferasirox (Exjade®) on Labile Plasma Iron Levels in Heavily Iron-Overloaded Patients with Transfusion-Dependent Anemias Enrolled in the Large-Scale, Prospective 1-Year EPIC Trial" @default.
• W159611377 doi "https://doi.org/10.1182/blood.v112.11.3881.3881" @default.
• W159611377 hasPublicationYear "2008" @default.
• W159611377 type Work @default.
• W159611377 sameAs 159611377 @default.
• W159611377 citedByCount "15" @default.
• W159611377 countsByYear W1596113772012 @default.
• W159611377 countsByYear W1596113772015 @default.
• W159611377 crossrefType "journal-article" @default.
• W159611377 hasAuthorship W159611377A5013521713 @default.
• W159611377 hasAuthorship W159611377A5026498330 @default.
• W159611377 hasAuthorship W159611377A5030898208 @default.
• W159611377 hasAuthorship W159611377A5036354175 @default.
• W159611377 hasAuthorship W159611377A5049244658 @default.
• W159611377 hasAuthorship W159611377A5053053769 @default.
• W159611377 hasAuthorship W159611377A5058078318 @default.
• W159611377 hasAuthorship W159611377A5069567664 @default.
• W159611377 hasAuthorship W159611377A5072237761 @default.
• W159611377 hasAuthorship W159611377A5081326206 @default.
• W159611377 hasAuthorship W159611377A5085429434 @default.
• W159611377 hasConcept C126322002 @default.
• W159611377 hasConcept C2777799968 @default.
• W159611377 hasConcept C2778248108 @default.
• W159611377 hasConcept C2778319317 @default.
• W159611377 hasConcept C2780007613 @default.
• W159611377 hasConcept C2780014101 @default.
• W159611377 hasConcept C2780817109 @default.
• W159611377 hasConcept C2781053155 @default.
• W159611377 hasConcept C2781440808 @default.
• W159611377 hasConcept C71924100 @default.
• W159611377 hasConcept C90924648 @default.
• W159611377 hasConceptScore W159611377C126322002 @default.
• W159611377 hasConceptScore W159611377C2777799968 @default.
• W159611377 hasConceptScore W159611377C2778248108 @default.
• W159611377 hasConceptScore W159611377C2778319317 @default.
• W159611377 hasConceptScore W159611377C2780007613 @default.
• W159611377 hasConceptScore W159611377C2780014101 @default.
• W159611377 hasConceptScore W159611377C2780817109 @default.
• W159611377 hasConceptScore W159611377C2781053155 @default.
• W159611377 hasConceptScore W159611377C2781440808 @default.
• W159611377 hasConceptScore W159611377C71924100 @default.
• W159611377 hasConceptScore W159611377C90924648 @default.
• W159611377 hasIssue "11" @default.
• W159611377 hasLocation W1596113771 @default.
• W159611377 hasOpenAccess W159611377 @default.
• W159611377 hasPrimaryLocation W1596113771 @default.
• W159611377 hasRelatedWork W1484640986 @default.
• W159611377 hasRelatedWork W1510055678 @default.
• W159611377 hasRelatedWork W2073806216 @default.
• W159611377 hasRelatedWork W2320817941 @default.
• W159611377 hasRelatedWork W2560653749 @default.
• W159611377 hasRelatedWork W2590626683 @default.
• W159611377 hasRelatedWork W2904391185 @default.
• W159611377 hasRelatedWork W3036602249 @default.
• W159611377 hasRelatedWork W4313204432 @default.
• W159611377 hasRelatedWork W4365813013 @default.
• W159611377 hasVolume "112" @default.
• W159611377 isParatext "false" @default.
• W159611377 isRetracted "false" @default.
• W159611377 magId "159611377" @default.
• W159611377 workType "article" @default.